Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
SciScore for 10.1101/2020.09.04.20187781: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Software and reproducibility: Data management was performed using Python 3.8 and SQL, and analysis using Stata 16.1. Pythonsuggested: (IPython, RRID:SCR_001658)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Previous investigations of hydroxychloroquine using observational data24 had limitations in their design and analysis,25 including relatively small sample sizes and …
SciScore for 10.1101/2020.09.04.20187781: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Software and reproducibility: Data management was performed using Python 3.8 and SQL, and analysis using Stata 16.1. Pythonsuggested: (IPython, RRID:SCR_001658)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Previous investigations of hydroxychloroquine using observational data24 had limitations in their design and analysis,25 including relatively small sample sizes and focusing only on hospitalised patients, which may produce spurious associations.26 Numerous randomised trials5–9 have failed to find any clinical benefit of hydroxychloroquine for treatment of COVID-19. Studies to date have also not demonstrated substantial harm, though the RECOVERY trial have shown some evidence of harm looking at death and ventilation as a composite outcome.27 While hydroxychloroquine has been approved for use in treatment of RA and SLE for many years, recent evidence has suggested potential short-term harms (when coprescribed with azithromycin).28 While we were underpowered to investigate co-medication with azithromycin, results of our study showed no evidence of an association with mortality from COVID-19 or other causes. This suggests justification to continue trials of hydroxychloroquine for prevention of COVID-19 to confirm our findings from observational data. Strengths and limitations: The greatest strengths of this study were the statistical power and the detailed longitudinal, routinely collected data to ascertain routine hydroxychloroquine use prior to the outbreak of COVID-19 in England. We were able to focus analyses on patients with indications for the use of hydroxychloroquine, a key component to mitigate confounding by indication in pharmacoepidemiological research of real-world d...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
